The Conversation (0)
NeuroMetrix Announces DPNCheck Collaboration Agreement with Fukuda Denshi for Japan Market
Nov. 16, 2018 08:24AM PST
Medical Device Investing
NeuroMetrix (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi for DPNCheck, the Company’s rapid, point-of-care test for diabetic peripheral neuropathy (DPN). As quoted in the press release: Fukuda Denshi Co. Ltd., recently hosted a roundtable discussion in Tokyo on the clinical importance of early diagnosis of diabetic peripheral neuropathy, quantitative …
NeuroMetrix (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi for DPNCheck, the Company’s rapid, point-of-care test for diabetic peripheral neuropathy (DPN).
As quoted in the press release:
Fukuda Denshi Co. Ltd., recently hosted a roundtable discussion in Tokyo on the clinical importance of early diagnosis of diabetic peripheral neuropathy, quantitative measurement, guidelines for staging of diabetic peripheral neuropathy for practical intervention, as well as appropriate tools for use in a clinical setting. Roundtable participants included leading Japanese academic clinicians and researchers, and Shai N. Gozani, M.D., Ph.D., NeuroMetrix, President and CEO.
“Fukuda Denshi has a significant presence in the healthcare professional market in Japan,” said Shai N. Gozani, M.D., Ph.D., NeuroMetrix President and CEO. “Their operating scale and commitment to expanding the use of DPNCheck are impressive. We look forward to growing the business together.”